INTRODUCTION {#sec0001}
============

Donor hematopoietic stem and progenitor cells for allogeneic hematopoietic stem cell transplantation (allo-HCT) are generally collected and infused fresh (ie, without cryopreservation) [@bib0001]. Limited data in patients undergoing HLA-matched related donor (MRD) allo-HCT using bone marrow (BM) as the graft source suggest that cryopreservation of the harvested marrow product does not impact hematopoietic recovery or the risk of graft-versus-host disease (GVHD) [@bib0002], [@bib0003], [@bib0004], [@bib0005]. Among recipients of peripheral blood (PB) allografts, some [@bib0006], but not all, studies [@bib0007] have reported delayed platelet recovery with cryopreserved grafts, but these studies have shown no impact of cryopreservation of PB allografts on neutrophil recovery, GVHD or survival outcomes.

The emergence of coronavirus disease 2019 (COVID-19) in Wuhan, China in December 2019 [@bib0008] and its rapid evolution into a pandemic not only has caused a serious healthcare crisis, but also has impacted the world economy and disrupted travel across international borders and within countries. These travel restrictions, combined with potentially reduced HCT donor availability (due to infection, quarantine, and constraints on travel to collection centers) and complex allograft processing logistics (ie, donor assessment, collection, and on-schedule delivery for fresh infusion), directly impact a transplantation center\'s ability to infuse fresh donor cells into intended recipients on the scheduled day of transplantation. Recognizing these challenges, both the American Society for Transplantation and Cellular Therapy (ASTCT) [@bib0009] and the National Marrow Donor Program (NMDP) [@bib0010] initially issued a strong recommendation that all unrelated donor (URD) products be delivered and cryopreserved at transplantation centers before initiation of patient conditioning. On March 23, 2020, the NMDP informed transplantation centers that starting on March 30, 2020, cryopreservation of URD grafts would be required before initiating conditioning in transplant recipients [@bib0010]. Many transplantation centers have instituted similar practices for HCT using cells from related donors.

Although published studies (all with limited patient numbers) suggest no significant impact of graft cryopreservation on outcomes of allo-HCT using conventional GVHD prophylaxis platforms (eg, calcineurin inhibitor-based), no data are available on whether this strategy is feasible for HCT using post-transplantation cyclophosphamide (ptCY)-based GVHD prophylaxis. Using the CIBMTR database, we evaluated the outcomes of patients undergoing ptCY-based allo-HCT for hematologic malignancies with either fresh or cryopreserved grafts, to inform clinical practice during the ongoing COVID-19 pandemic.

METHODS {#sec0002}
=======

*Data Sources* {#sec0003}
--------------

The CIBMTR is a working group of more than 380 transplantation centers worldwide that contribute detailed data on HCT to a central coordinating center managed by the NMDP and the Medical College of Wisconsin. Participating centers are required to report all transplantations consecutively, and compliance is monitored by onsite audits. Computerized checks for discrepancies, physicians' review of submitted data, and onsite audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. The NMDP's Institutional Review Board, which is the board of record for the CIBMTR\'s database protocols, approved this study.

The CIBMTR collects data at 2 levels: transplant essential data (TED) and comprehensive report form (CRF) data. TED include disease type, age, sex, pre-HCT disease stage and chemotherapy responsiveness, date of diagnosis, graft type, conditioning regimen, post-transplantation disease progression and survival, development of a new malignancy, and cause of death. All CIBMTR centers contribute TED. More detailed disease and pretransplantation and post-transplantation clinical information is collected from a subset of registered patients selected for CRF data by a weighted randomization scheme. TED- and CRF-level data are collected pretransplantation, 100 days and 6 months post-transplantation, and annually thereafter or until death. Data for the current analysis were retrieved from CIBMTR (TED and CRF) report forms, considering all patients for whom a CRF 2006 form (collecting details of graft manipulation and composition) was submitted.

Patients {#sec0004}
--------

Included in this analysis are adults (age ≥18 years) undergoing allo-HCT between 2013 and 2018 for hematologic malignancies with ptCY (with or without calcineurin inhibitor and/or mycophenolate mofetil) as the GVHD prophylaxis. Diagnosis was limited to acute leukemias in first or second complete remission (CR1/CR2), chronic leukemias, or myelodysplastic syndrome (with \<5% blasts at HCT) and lymphomas. Donors included MRDs, haploidentical related donors, matched URDs, and mismatched URDs. Umbilical cord blood grafts were not included because of universal cryopreservation.

Definitions and Study Endpoints {#sec0005}
-------------------------------

The primary study endpoint was overall survival (OS); death from any cause was considered an event and surviving patients were censored at last contact. Secondary endpoints included hematopoietic recovery, acute and chronic GVHD, non-relapse mortality (NRM), progression/relapse and disease-free survival (DFS). NRM was defined as death without evidence of disease relapse/progression; relapse was considered a competing risk. Relapse/progression was defined as morphologic, cytogenetic, or molecular disease recurrence for leukemias and myeloid malignancies and as progressive lymphoma after HCT or lymphoma recurrence after a CR; NRM was considered a competing risk. For DFS, a patient was considered a treatment failure at the time of relapse/progression or death from any cause. Patients alive without evidence of disease relapse or progression were censored at last follow-up.

Neutrophil recovery was defined as the first of 3 successive days with absolute neutrophil count ≥500/µL after the post-transplantation nadir. Platelet recovery was considered to have occurred on the first of 3 consecutive days with platelet count ≥20,000/µL in the absence of platelet transfusion for 7 consecutive days. For neutrophil and platelet recovery, death without the event was considered a competing risk. The intensity of allo-HCT conditioning regimens was categorized as myeloablative (MAC) or reduced-intensity/nonmyeloablative conditioning (RIC/NMA) using consensus criteria [@bib0011]. Disease Risk Index (DRI) was assigned as reported previously [@bib0012]. Acute GVHD [@bib0013] and chronic GVHD [@bib0014] were graded using standard criteria. For calculation of acute and chronic GVHD incidences, death without the event was considered a competing risk.

Statistical Analysis {#sec0006}
--------------------

A total of 277 patients were identified who met the aforementioned eligibility criteria and who received cryopreserved grafts and 4083 patients who met eligibility criteria and received fresh graft infusion. A mixed method of direct matching and propensity score matching was applied before the analyses to obtain a control groups with similar clinical characteristics. The propensity score is the probability of a given patient to receive the cryopreserved graft, based on that patient\'s observed covariates. The propensity score was predicted for each patient using logistic regression accounting for following risk factors: disease histology (acute myelogenous leukemia versus acute lymphocytic leukemia versus chronic myelogenous leukemia versus chronic lymphocytic leukemia versus myelodysplastic syndrome versus non-Hodgkin lymphoma versus Hodgkin lymphoma), Karnofsky Performance Score (KPS) (≥90% versus \<90%), HCT-Comorbidity Index (HCT-CI) (0 versus 1 to 2 versus ≥3), conditioning intensity (MAC versus RIC/NMA), donor type (MRD versus haploidentical related donor versus 8/8 matched URD versus ≤7/8 URD) and recipient race. Two patients with equal propensity scores meant they had similar probabilities of receiving a cryopreserved graft. The distributions of estimated propensity scores between cryopreserved and fresh grafts were examined. We then matched each recipient of a cryopreserved graft with controls receiving fresh grafts, by matching on 4 covariates: graft type (BM versus PB), DRI (low risk versus intermediate risk versus high risk), recipient age (within 5 years), and propensity score (within 1 standard deviation from the pooled sample). The following procedure was adopted to find a maximum of 4 fresh graft controls for each cryopreserved graft case:1.Identify all potential matched controls for each case.2.Assign the control with the smallest age difference with the case. If there were multiple controls with the same age difference, assign one at random.3.Repeat steps 1 and 2 four times, to identify 4 controls.

We matched a total of 1080 controls to 274 cases, including 266 cases matched to 4 controls, 3 cases matched to 3 controls, 2 cases matched to 2 controls, and 3 cases matched to a single control. Three cases with no matched controls were excluded.

Patient-, disease-, and transplantation-related factors were compared between matched cases and controls using the chi-square test for categorical variables and the Mann-Whitney *U* test for continuous variables. The Kaplan-Meier estimator was used to evaluate the probability of OS and DFS [@bib0015]. Cumulative incidence rates were calculated for hematopoietic recovery, GVHD, NRM, and relapse while accounting for competing events [@bib0016]. The marginal Cox model was applied to evaluate the main treatment effect while adjusting for the potential correlation within each matched pair. The assumption of proportional hazards for the main risk factor (cryopreserved graft versus fresh graft) for each outcome was tested by adding a time-dependent covariate. Hazard ratios (HRs) with 95% confidence intervals (CIs) and *P* values were reported for each clinical outcome of interest, comparing the cryopreserved graft treatment group with the fresh graft group. Because of the large number of comparisons performed, only *P*values \<.01 were considered statistically significant a priori. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC).

RESULTS {#sec0007}
=======

Baseline Characteristics {#sec0008}
------------------------

A total of 1354 patients were included in the analysis, of whom 1080 received fresh grafts and 274 received cryopreserved grafts. The baseline patient-, disease-, and transplantation-related characteristics are summarized in [Table 1](#tbl0001){ref-type="table"} . The 2 cohorts were similar in terms of median patient age, sex, race, KPS, diagnosis, DRI, HCT-CI, donor/graft source, conditioning intensity, and donor-recipient cytomegalovirus serostatus. Acute leukemias constituted the most common diagnoses, and haploidentical related donors were the most common donor source in both cohorts. BM was the graft source in only \~6% of the procedures. The median follow-up of survivors was 24 months (range, 3 to 77 months) in the fresh graft cohort and 23 months (range, 3 to 68 months) in the cryopreserved graft cohort.Table 1Baseline Characteristics of the Propensity Score-Matched Patient Population (2013 to 2018)Table 1CharacteristicFresh GraftsCryopreserved Grafts*P* ValueNumber of patients1080274Age at transplantation, yr, median (range)52 (19-80)55 (22-75).33Male sex, n (%)620 (57.4)163 (59.5).53Karnofsky performance score ≥90, n (%)536 (49.6)137 (50).71Not reported, n (%)13 (1.2)5 (1.8)Race, n (%).98Caucasian738 (68.3)187 (68.2)African-American205 (19)53 (19.3)Others66 (6.1)15 (5.5)Not reported71 (6.6)19 (6.9)Disease, n (%).66Acute myelogenous leukemia431 (39.9)107 (39.1)Acute lymphoblastic leukemia228 (21.1)55 (20.1)Chronic leukemias78 (7.2)28 (10.2)Myelodysplastic syndrome172 (15.9)46 (16.8)Lymphoma171 (15.9)38 (13.8)Disease risk index, n (%)1.00Low114 (10.6)29 (10.6)Intermediate715 (66.2)181 (66.1)High251 (23.2)64 (23.4)HCT-CI, n (%).170192 (17.8)36 (13.1)1-2324 (30)90 (32.8)≥3564 (52.2)148 (54)Donor/recipient CMV serostatus, n (%).41-/+289 (26.8)76 (27.7)Other combinations786 (72.8)197 (71.9)Not reported5 (.5)1 (.4)Conditioning intensity, n (%).80Myeloablative515 (47.7)133 (48.5)Reduced-intensity/nonmyeloablative565 (52.3)141 (51.5)Donor type, n (%).18Matched related donor152 (14.1)49 (17.9)Haploidentical related donor659 (61)169 (61.7)8/8 unrelated donor182 (16.9)34 (12.4)≤7/8 unrelated donor87 (8.1)22 (8)Graft type, n (%)1.00BM71 (6.6)18 (6.6)PB1009 (93.4)256 (93.4)TNC dose infused in BM grafts, × 10^8^/kg recipient body weight, median (range)3.1 (1.2-26.3)2.9 (1.8-4.6).85CD34^+^ cell dose infused in PB grafts, × 10^6^/kg recipient body weight, median (range)5.3 (1-24.5)5.2 (1.1-13.7).03[^2]

OS {#sec0009}
--

Two-year OS rates were 60.6% (95% CI, 57.3% to 63.8%) in the fresh graft cohort and 58.7% (95% CI, 51.9% to -65.4%) in the cryopreserved graft cohort (*P*= .62) ([Figure 1](#fig0001){ref-type="fig"} A, [Table 2](#tbl0002){ref-type="table"} ). In matched pair regression analysis, graft cryopreservation was not associated with a significantly higher risk of mortality (HR for cryopreserved versus fresh, 1.05; 95% CI, .86% to 1.29%; *P*= .60) ([Table 3](#tbl0003){ref-type="table"} ).Figure 1Outcomes of ptCY-based allogeneic HCT with either fresh or cryopreserved grafts. (A) OS. (B) Cumulative incidence of chronic GVHD.Figure 1Table 2Univariate Outcomes of the Matched PopulationTable 2OutcomesFresh (N = 1080)Cryopreserved (N = 274)nProb (95% CI), %nProb (95% CI), %*P* ValueNeutrophil recovery107527028 days93.8 (92.3-95.1)93.3 (90-96).80Platelet recovery1076270100 days88.8 (86.8-90.6)87.7 (83.4-91.4).62Grade II-IV acute GVHD1040271100 days31.3 (28.5-34.1)34 (28.5-39.8).40Grade III-IV acute GVHD1040271100 days9.4 (7.7-11.3)6.3 (3.7-9.5).07Chronic GVHD10772721 year30.7 (27.9-33.5)26.8 (21.5-32.5).222 years36.4 (33.4-39.6)29.5 (23.8-35.5).04Relapse/progression10622731 year24.1 (21.6-26.8)24.7 (19.7-30.1).852 years30.7 (27.7-33.7)36.3 (29.9-42.9).13NRM10622731 year15.8 (13.7-18.1)16.9 (12.6-21.7).672 years19 (16.5-21.5)22 (16.8-27.7).32DFS10622731 year60 (57-63)58.4 (52.4-64.3).632 years50.4 (47-53.7)41.7 (35-48.6).03OS10802741 year71.1 (68.3-73.8)70.3 (64.6-75.7).812 years60.6 (57.3-63.8)58.7 (51.9-65.4).62Table 3Matched-Pair Analysis by Marginal Cox ModelTable 3OutcomesCryopreserved Grafts, HR (95% CI)Fresh Grafts, HR (Reference)*P* ValueNeutrophil recovery.91 (.80-1.02)1.12Platelet recovery.88 (.78-1.00)1.05Grade II-IV acute GVHD1.10 (.87 -1.38)1.43Grade III-IV acute GVHD.78 (.50-1.22)1.27Chronic GVHD.78 (.61-.99)1.04Relapse/progression1.21 (.97-1.50)1.09NRM1.16 (.86-1.55)1.32DFS1.19 (1.01 -1.40)1.04OS1.05 (.86-1.29)1.60

Hematopoietic Recovery and GVHD {#sec0010}
-------------------------------

The day +28 cumulative incidence of neutrophil recovery was 93.8% (95% CI, 92.3% to 95.1%) in the fresh graft cohort and 93.3% (95% CI, 90% to 96%) in the cryopreserved graft cohort (*P* = .80) ([Table 2](#tbl0002){ref-type="table"}). The corresponding median times to neutrophil recovery were 16 days (range, 5 to 69 days) and 17 days (range, 8 to 48 days; *P* = .05). The respective day +100 cumulative incidences of platelet recovery were 88.8% (95% CI, 86.8% to 90.6%) and 87.7% (95% CI, 83.4% to 91.4%) (*P* = .62; [Table 2](#tbl0002){ref-type="table"}). The corresponding median times to platelet recovery were 24 days (range, 1 to 321 days) and 26 days (range, 7 to 351 days; *P* = .007). In matched-pair regression analysis, graft cryopreservation was not associated with significantly delayed neutrophil recovery (HR, .91; 95% CI, .80 to 1.02; *P* = .12) or platelet recovery (HR, .88; 95% CI, .78 to 1.00; *P* = .05; [Table 3](#tbl0003){ref-type="table"}).

The cumulative incidence of grade II-IV acute GVHD at day +100 ([Table 2](#tbl0002){ref-type="table"}) was 31.3% (95% CI, 28.5% to 34.1%) in the fresh graft group and 34% (95% CI, 28.5% to 39.8%) in the cryopreserved graft group (*P* = .40). Corresponding rates of grade III-IV acute GVHD were 9.4% (95% CI, 7.7% to 11.3%) and 6.3% (95% CI, 3.7% to 9.5%) (*P* = .07). In matched-pair regression analysis ([Table 3](#tbl0003){ref-type="table"}), the 2 cohorts had similar risks of grade II-IV (HR, 1.10; 95% CI, .87 to 1.38; *P* = .43) and grade III-IV acute GVHD (HR, .78; 95% CI, .50 to 1.22; *P* = .27). The cumulative incidence of chronic GVHD at 1 year was 30.7% (95% CI, 27.9% to 33.5%) in the fresh graft cohort and 26.8% (95% CI, 21.5% to 32.5%) in the cryopreserved graft cohort (*P* = .22; Figure 1B, Table 2). In matched-pair regression analysis ([Table 3](#tbl0003){ref-type="table"}), cryopreserved grafts were associated with a lower risk of chronic GVHD (HR, .78; 95% CI, .61% to .99%) but this was of only borderline statistical significance (*P* = .04).

NRM, Relapse/Progression, and DFS {#sec0011}
---------------------------------

The 2-year rate of NRM was 19.0% (95% CI, 16.5% to 21.5%) in the fresh graft cohort and 22.0% (95% CI, 16.8% to 27.7%) in the cryopreserved graft cohort (*P* = .32). The corresponding rates of relapse/progression were 30.7% (95% CI, 27.7% to 33.7%) and 36.3% (95% CI, 29.9% to 42.9%) (*P* = .13), and corresponding rates of DFS were 50.4% (95% CI, 47% to 53.7%) and 41.7% (95% CI, 35% to 48.6%) (*P* = .03) ([Table 2](#tbl0002){ref-type="table"}). In matched-pair regression analysis, the HRs for NRM (1.16; 95% CI, .86 to 1.55; *P* = .32) and relapse/progression (1.21; 95% CI, .97 to 1.50; *P* = .09) were not statistically significant, whereas the HR for treatment failure (inverse of DFS) was of borderline significance (1.19; 95% CI, 1.01 to 1.29; *P* = .04) (Table 3).

DISCUSSION {#sec0012}
==========

Prospective, randomized data comparing outcomes of ptCY-based allo-HCT using fresh versus cryopreserved grafts are not available. Using the CIBMTR database, we evaluated the 2 approaches retrospectively, using available data to adjust for known covariates. The most important finding of our analysis is that OS out to 2 years was virtually identical with fresh grafts and cryopreserved grafts. Second, there was no evidence of significantly delayed hematopoietic recovery or higher risks of either acute or chronic GVHD with cryopreservation. Marginal increases in relapse/progression and marginal decreases in chronic GVHD and DFS are of uncertain significance given the multiple comparisons in the study and the fact that this was not a randomized study. In fact, a key piece of information was unavailable to us, which is why these grafts were cryopreserved. One can reasonably assume that this was not a random decision. Although some delays might be precipitated by donor scheduling issues, many were likely influenced by clinical events necessitating requiring a delay in transplantation, and these events themselves might be indicators of prognosis (eg, delay because of the need for chemotherapy to achieve better pretransplantation disease control). Given this background, the similar survival outcomes are particularly reassuring.

A rapidly growing body of literature shows good outcomes of ptCY-based allo-HCT in patients with both myeloid [@bib0017], [@bib0018], [@bib0019], [@bib0020] and lymphoid malignancies [@bib0021], [@bib0022], [@bib0023], [@bib0024], [@bib0025], validating the seminal observations from the Johns Hopkins group [@bib0020]. Administration of ptCY potentially mitigates the risk of GVHD by targeting alloreactive T cells that are rapidly proliferating early after stem cell infusion, and by relatively sparing regulatory T cells and leaving the nondividing hematopoietic stem and progenitor cells unaffected [@bib0020]. Whether the proliferation kinetics of thawed alloreactive T cells different from those of fresh cells is not known. Murine data suggest that freezing and thawing of regulatory T cells results in loss of CD62L expression and a reduced capacity to protect against GVHD [@bib0026]. In addition, limited data indicate that cryopreservation can increase the sensitivity of porcine PB mononuclear cells (stimulated by phorbol myristate acetate) for IFN-γ production, but not for IL-6 production [@bib0027]. Despite these preclinical observations, our analysis did not reveal any clinically relevant differences in hematopoietic recovery kinetics, acute GVHD risk, or OS between fresh versus cryopreserved grafts for patients undergoing ptCY-based allo-HCT. Limited data in allo-HCT (with non-ptCY-based GVHD prophylaxis) using either BM [@bib0002], [@bib0003], [@bib0004], [@bib0005] or PB \[[@bib0006],[@bib0007]\] as the graft source also show no impact of cryopreservation on hematopoietic recovery, GVHD, or survival outcomes. Although of uncertain clinical significance, the observations of lower chronic GVHD and DFS warrant further investigation, especially probing the impact on the freeze-thaw cycle on functional profile of immune effector cells. However, in the ongoing COVID-19 pandemic, necessitating cryopreservation of all URD grafts and the majority of related donor products, our data do not show a net safety signal against the use of ptCY-based platforms with frozen products. In this ongoing global outbreak, the ability to cryopreserve allografts has obvious logistical advantages, the most important being the ability to secure a graft before myeloablative therapy in a transplant recipient. Even under normal circumstances, it is sometimes advantageous to ensure the availability of an optimal stem cell dose before the start of conditioning (eg, in the setting of major donor/recipient weight discrepancy and/or advanced donor age).

Our current analysis also underscores the value of observational transplant registries like CIBMTR that can be quickly leveraged to examine critical clinical questions to inform practice and improve patient care, even in unexpected emergencies.

We must acknowledge the limitations of our analysis. Despite propensity score matching, our analysis cannot adjust for unknown clinical parameters influencing the decision to use cryopreservation. We cannot assess the impact of cryopreservation on graft viability (compared with a fresh graft) or examine functional characteristics of thawed immune effector cells. We also acknowledge that chronic GVHD rates across both cohorts in the current analysis are higher than those originally reported with ptCY [@bib0020], likely a reflection of increased use of PB grafts in clinical practice [@bib0028]. BM grafts were underrepresented in our study, and thus we suggest caution in interpreting these results.

In conclusion, our analysis provides evidence that for patients undergoing ptCY-based allo-HCT, cryopreservation of donor allografts, although not fully understood, appear to be safe and thus suitable for patients during the current worldwide crisis, and perhaps in other settings more broadly.
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